Universe Pharmaceuticals INC
UPC Nasdaq
SEC CIK 1809616
Follow Universe Pharmaceuticals
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $17.9B | −$3.7B |
| FY24 | $23B | −$8.7B |
| FY23 | $32.3B | −$6.6B |
| FY22 | $40.1M | −$7.9M |
| FY21 | $48M | $11.3M |
| FY20 | $30.7M | $7.6M |
| FY19 | $33.2M | $7.6M |
| FY18 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 35.3% | −16.3% | −20.6% |
| FY24 | 26.4% | −34.8% | −37.9% |
| FY23 | 31.9% | −12.3% | −20.4% |
| FY22 | 54.5% | −17.5% | −19.7% |
| FY21 | 52.8% | 28.3% | 23.6% |
| FY20 | 45.9% | 33.4% | 24.6% |
| FY19 | 40.3% | 29.4% | 22.7% |
| FY18 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$5.3B |
| FY24 | −$9.7B |
| FY23 | $1.1B |
| FY22 | −$1.4M |
| FY21 | −$2.5M |
| FY20 | $6.1M |
| FY19 | $13.1M |
| FY18 | - |
- Universe Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Universe Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −20.6% | −30.6% |
| FY24 | −37.9% | −47% |
| FY23 | −20.4% | −58% |
| FY22 | −19.7% | −80.4% |
| FY21 | 23.6% | −71.9% |
| FY20 | 24.6% | −62.2% |
| FY19 | 22.7% | −46.3% |
| FY18 | - | −49.6% |